Although not yet tested in OSA, clinical trials using IL-8 monoclonal antibodies in other cancers types are ongoing (108) and provide an interesting target given the links between increased IL-8 expression and doxorubicin resistance (109, 110). The gene discussed is CXCL8; the disease is cancer.